Abstract?AIM: To discuss clinical efficacy and safety of 10g/L atropine with short covering for children with amblyopia.?METHODS: Eighty -eight children ( 88 eyes ) with amblyopia, staying in hospital from February 2011 to February 2014 for treatment, were divided into control group ( n =44 ) and observation group ( n =44 ) . The control group only given short covering therapy was observed.Observation group was given 10g/L atropine treatment besides covering.Clinical efficacy, treatment compliance, visual acuity, corrected spherical degree of amblyopia eye and adverse events were observed and compared.?RESULTS:1) After treatment, total effective rate of the observation group was 95% ( 42/44 ) , significantly higher than that of control group ( 80%, 35/44, P<0.05 ); 2 ) excellent compliance rate of the observation group was 95% ( 42/44 ) , significantly higher than that of control group (82%, 36/44, P<0.05);3) visual acuity of the two groups when the disease was first diagnosed was not significantly different (P>0.05), but increased number of lines of vision and corrected spherical degree of amblyopia eye in the observation group were significantly higher (P<0.05);4) in the observation group total rate of adverse events was 9% ( 4/44 ) , significantly lower than that in the control group (23%, 10/44, P<0.05).?CONCLUSION: The combined therapy, 1% atropine with short covering, is effective and safe for amblyopia in children.

Objective To assess the immediate efficacy of transcatheter closure of patent ductus arteriosus(PDA) using the angled duct occluder(ADO). Methods 9 patients(1 male, 8 female) underwent transcatheter closure of PDA using the ADO. The mean PDA diameter at its narrowest segment was (5.8?1.9) mm, ranging 3 to 10 mm. A 6-9F long sheath was used for the delivery of ADO. Results The devices were deployed successfully in all patients. Angiographies showed no shunt across the device 15 min after the implatation of ADO. Within 1 week, echocardiography revealed complete closure in all patients. There were no complications. Conclusions The transcatheter closure of PDA using ADO is an effective and safe procedure. The device matches with the shape of aortic cavity much more precisely than Amplatzer duct occluder.

Objective To evaluate the efficacy and safety of transcatheter closure of perimembranous ventricular septal defects (VSD) using home-made nitinol asymmetric two-disk occluder.Methods Trans-catheter closure was attempted in 16 patients with perimembranous ventricular septal defect at a mean age of (16.8 ?11.2) years (range from 5 to 37 years). All patients were diagnosed by the physical examination, echocardiography and left ventriculography. The mean VSD narrowest diameter was (4.31 ?1.35)mm (range from 3 to 8mm) by echocardiography. A 6—8F delivery sheath was advanced across the perimembranous VSD over a wire from femoral vein approach. Left ventriculography and transthoracic echocardiography were repeated to assess the efficacy of the closure, 15min after the procedure. Results The mean VSD narrowest diameter was (4.63 ?1.59)mm (range from 3 to 8 mm) measured by left ventriculography. The distance of upper rim of VSD to aortic valve was 1? ?.6 ( 3.31 ?1.9) mm. The devices were successfully deployed in all patients. The diameter of occluder was (6.19 ?1.91)mm (range from 4 to 10mm). There were a trivial residual shunt in 2 patients by left ventriculography and the transthoracic echocardiography after the procedure. No shunt was found by the transthoracic echocardiography 1 week after the procedure. No complication occurred in all patients. Conclusion Transcatheter closure of membranous VSD with home made nitionol asymmetric two-disk occluder is safe and effective. The long-term efficacy is still to be determined by follow-up.

Objective To assess the efficacy and safety of transcatheter closure of intracristal ventricular septal defect (IVSD) and subpulmonary ventricular septal defect(SVSD)with home-made eccentric nitinol occluder.Methods Transcatheter closure was attempted in 28 patients (15 men and 13 women), with IVSD(n=22)and SVSD(n=6) at a age of 12.44?5.86 years (ranged from 3 to 34 years of age) The homemade device consists of two low profile disks made of Nitinol wire mesh with a 2 mm connecting waist. The left disk is 6 mm towards the apex and 0 mm towards the aortic valve. The right disk is 4 mm larger than the waist. The devices were deployed via the femoral vein using 7-10 Fr sheaths with the guidance of transthoracic echocardiography and fluoroscopy. Results The VSD diameter was 4.54 ?1.93 mm (ranged 2 to 12 mm). the distance of VSD to aortic valve was 0.35?045 mm (range 0 to 1 mm )。The connecting waist diameter of device was 7.65?3.11 mm(ranged 4 to 14 mm). The device was implanted successfully in 26 of 28 procedures. There was a trivial aortic regurgtation in 1 patient with SVSD after deployment of the occluder. Implantation was unsuccessful in 2 patients with SVSD, with having large defects. No other complications were observed. The mean fluoroscopy time for the procedure was 14.07?5.19 min (range 9 to 40 min). The procedure time was 59.81?17.76 min (range 40 to 150 min).Conclusions Transcatheter closure of IVSD and SVSD with homemade eccentric nitinol occluder is effective, easy and safe.Longer follow-up is required to assess long-term efficacy.

Objective To assess the efficacy and safety of transcatheter closure of intracristal ventricular septal defect (IVSD) and subpulmonary ventricular septal defect (SVSD) with home-made eccentric nitinol occluder.Methods Transcatheter closure was attempted in 28 patients (15 men and 13 women), with IVSD (n=22) and SVSD (n=6) at an average of 12.44 ?5.86 years (ranged from 3 to 34 years of age). The homemade device consists of two low profile disks made of Nitinol wire mesh with a 2 mm connecting waist. The left disk is 6 mm towards the apex and 0 mm towards the aortic valve. The right disk is 4 mm larger than the diameter of the waist. The devices were depolyed via the femoral vein using 7-10 Fr sheaths under the guidance of transthoracic echocardiography and fluoroscopy. Results The VSD average diameter was 4.54 ?1.93mm (ranged 2 to 12 mm) with the distance of VSD to aortic valve averaging 0.35 ?0.45mm (range 0 to 1 mm) and the connecting waist diameter of device of 7.65 ?3.11 mm (ranged 4 to 14 mm). The device was implanted successfully in 26 of 28 procedures. A trivial aortic regurgitation occurred in 1 patient with SVSD after deployment of the occluder. Implantation was unsuccessful in 2 patients with SVSD having large septal defects. No other complications were observed. The mean fluoroscopy time for the procedure was 14.07 ?5.19 min (range 9 to 40 min) and the whole procedure time was 59.81 ?17.76min(range 40 to 150 min).Conclusions Transcatheter closure of IVSD and SVSD with homemade eccentric nitinol occluder is effective, easy and safe. Longer term follow-up is necessary for assessing the efficacy.

Tumor growth depends on the tumor microenvironment(TME).Tumor-associated neutrophils(TANs)are important inflammatory cells in TME.TANs are divided intoN1type with anti-tumor effect andN2type of tumor-promoting effect.Therefore,TANs have both beneficial and harmful aspects of the body.A large number of studies have been shown that TANs affect tumor formation,metastasis,angiogenesis and immune response,regulated by the secretion of cytokines and chemokines.This review will summarize the biological characteristics of TANs,and tumor development,prognosis and treatment of tumor as well as research progress of the relationship between TANs and tumor.

Objective: To examine the hypodontia in orthodontic patients and to investigate the correlation between the hypodontia and skeletal class. Methods:The hypodontia were determined by panoramic radiographs,and skeletal class were evaluated by lateral cephalograms. The correlation between the hypodontia and skeletal class were analyzed by statistic methods. Results:The number of hypodontia in anterior upper arch was higher than those in lateral upper arch and the number of hypodontia in anterior lower arch was higher than those in lateral upper arch (P

Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Child, Preschool ; China ; epidemiology ; Female ; Humans ; Infant ; Male ; Middle Aged ; Occupational Exposure ; prevention & control ; Poisoning ; epidemiology ; Young Adult

OBJECTIVE:To explore risk factors for the death in HIV/AIDS patients suffering from myelosuppression during highly active antiretroviral therapy(HAART)treatment. METHODS:The historical cohort study method was used to choose 735 in-patients from Nanning Forth People's Hospital during Jan. 2011 to Jul. 2015. Univariate and multivariate Logistic regression analy-sis were used to show the risk factors for the death. RESULTS:Of 735 cases,there were 648 survival cases and 87 dead cases, with mortality of 11.8%. Univariate Logistic analysis showed that:male,elder,higher total bilirubin,lower creatinine clearance, lower CD4+T cell count in baseline,combined more opportunistic infection,combined more myelosuppressive drugs,thrombocyto-penia,lower hemoglobin were the risk factors for the death of HIV patients with myelosuppression in HARRT treatment,while route of HIV infection,HAART treatment A including Zidovudine,weight were the protective factors. Multivariate Logistic regres-sion analysis showed male,elder,higher total bilirubin,lower creatinine clearance,lower CD4+ T cell count in baseline,com-bined more opportunistic infection,combined more myelosuppressive drugs,thrombocytopenia,lower hemoglobin were the risk factors for the death of HIV patients with myelosuppression in HARRT treatment too. CONCLUSIONS:Pertinence treatment and control methods for HIV/AIDS with myelosuppression in HARRT treatment should be taken to reduce the mortality in the future.

The tumor microenvironment plays a vital role in the process of tumorigenesis and development.Studies have been confirmed that the tumor microenvironment heterogeneity has a huge impact on the tumor efficacy and drug resistance.This review summarizes the relationship between immune cells and related immune factors in tumor microenvironment as well as vascular endothelial cell heterogeneity and tumor progression and prognosis.So it is better help us understand the tumor microenvironment heterogeneity for the impact of the tumor.This will conduce to us through a variety of methods to enhance the body's anti-tunor ability by inhibi-ting and killing tumor cells.